<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954172</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI305A301</org_study_id>
    <nct_id>NCT02954172</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC</brief_title>
  <official_title>Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WuXi CDS Clinical Research (Shanghai) Co.Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double blind, multicenter phase3 study .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double blind, multicenter phase3 study in chemotherapy naive patients with&#xD;
      stage IIIB,IV or recurrent NSCLC of non-squamous. the study will randomize about 436 patients&#xD;
      at a 1:1 ratio to 2 treatment arms. The study is divided 4 phase, screening, combination&#xD;
      treatment, maintenance and follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2016</start_date>
  <completion_date type="Actual">November 12, 2019</completion_date>
  <primary_completion_date type="Actual">October 19, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>18 weeks</time_frame>
    <description>ORR（objective response rate）was defined as the percentage of participants in the analysis population who had a Complete Response or a Partial Response per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Time</measure>
    <time_frame>18.020 months</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>18 months</time_frame>
    <description>Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by Independent Radiological Review Committee.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Bevacizumab in Combination With Paclitaxel/Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI305 in Combination with Paclitaxel/Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab in Combination With Paclitaxel/Carboplatin</intervention_name>
    <description>Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
    <arm_group_label>Bevacizumab in Combination With Paclitaxel/Carboplatin</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI305 in Combination with Paclitaxel/Carboplatin</intervention_name>
    <description>Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
    <arm_group_label>IBI305 in Combination with Paclitaxel/Carboplatin</arm_group_label>
    <other_name>Bevacizumab Biosimilar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. signed inform consent form(ICF)&#xD;
&#xD;
          2. Age ≥ 18 years and ≤ 75 years, male or female&#xD;
&#xD;
          3. Histologically or cytologically documented inoperable, local advanced (stage IIIB),&#xD;
             metastatic (stage IV), or recurrent non-squamous NSCLC; Mixed tumors should be&#xD;
             categorized according to the predominant cell type&#xD;
&#xD;
          4. Histologically confirmed epidermal growth factor receptor (EGFR) wild type or&#xD;
             insensitive mutation&#xD;
&#xD;
          5. At least one measurable lesion according to Response Evaluation Criteria In Solid&#xD;
             Tumors（RECISIT） v 1.1&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1&#xD;
&#xD;
          7. Life expectancy ≥ 6 months&#xD;
&#xD;
          8. Laboratory results:&#xD;
&#xD;
               1. Adequate hematologic function, defined as absolute neutrophil count ≥1.5×10^9 /L,&#xD;
                  platelet count ≥100 ×10^9 /L, hemoglobin ≥90g/L;&#xD;
&#xD;
               2. Adequate liver function, defined as total bilirubin levels ≤ 1.5 times normal&#xD;
                  upper limit (ULN), and aspartate aminotransferase (AST) and alanine&#xD;
                  aminotransferase (ALT) levels ≤ 2.5 times ULN, or AST and ALT levels ≤ 5 times&#xD;
                  ULN for patients with hepatic metastasis;&#xD;
&#xD;
               3. Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN or&#xD;
                  creatinine clearance ≥ 50 ml / min (Cockcroft-Gault formula) and proteinuria &lt;&#xD;
                  2+;&#xD;
&#xD;
               4. Coagulation function is adequate, defined as international normalized ratio (INR)&#xD;
                  or prothrombin time (PT) ≤ 1.5 times normal upper limit (ULN), PTT or aPTT ≤ 1.5&#xD;
                  times ULN;&#xD;
&#xD;
          9. Expected protocol compliance&#xD;
&#xD;
         10. Patients of childbearing potential must agree to use effective contraceptive measures&#xD;
             during study treatment and for 6 months after receiving last study treatment (e.g.&#xD;
             abstinence, sterilization surgery, oral contraceptives, contraception by progesterone&#xD;
             injection or subcutaneous).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior chemotherapy or target therapy with another systemic anti-cancer agent (e.g.,&#xD;
             monoclonal antibody, tyrosine kinase inhibitor) for the treatment of the patient's&#xD;
             current stage of disease (Stage IIIB not amenable for combined modality treatment,&#xD;
             stage IV or recurrent disease). Prior surgery and irradiation is permitted, provided&#xD;
             that the criteria outlined in the protocol for both treatments are met. Disease&#xD;
             progressed within 6 months after adjuvant therapy must be excluded.&#xD;
&#xD;
          2. Mixed non-small cell and small cell carcinoma, or mixed adenosquamous carcinomas with&#xD;
             predominant squamous cell&#xD;
&#xD;
          3. Histologically or cytologically confirmed EGFR sensitive mutation type, unknown EGFR&#xD;
             status for any reason is allowed in this study.&#xD;
&#xD;
          4. Known hemoptysis within 3 months prior to screening with blood volume more than 2.5 mL&#xD;
             each time&#xD;
&#xD;
          5. Evidence of tumor invading major blood vessels on imaging. The investigator or the&#xD;
             local radiologist must exclude evidence of tumor that is fully contiguous with,&#xD;
             surrounding, or extending into the lumen of a major blood vessel (e.g., pulmonary&#xD;
             artery or superior vena cava)&#xD;
&#xD;
          6. Evidence of brain metastasis, spinal cord compression or carcinomatous meningitis&#xD;
             history with clinical symptoms. For stable patients with no symptom, could be admitted&#xD;
             if fulfill all below criteria: measurable lesion(s) out of CNS, no metastasis at&#xD;
             mesocephalon, annular protuberance, medulla oblongata and spinal cord; no history of&#xD;
             intracranial bleeding.&#xD;
&#xD;
          7. Radical radiotherapy to the thorax with curative intent within 28 days prior to&#xD;
             enrollment; palliative radiotherapy for bone lesions outside the thoracic region&#xD;
             within 2 weeks prior to first dose of study treatment.&#xD;
&#xD;
          8. Serious, non-healing wound, active ulcer, or untreated bone fracture, or major&#xD;
             surgical procedure within 28 days prior to randomization or anticipation of need for&#xD;
             major surgery during the course of the study.&#xD;
&#xD;
          9. Minor surgery (Including insertion of an indwelling catheter) within 48 hours prior to&#xD;
             first dose of study treatment&#xD;
&#xD;
         10. Recent or current (within 10 days prior to first dose of study treatment) receive&#xD;
             treatment of Aspirin (&gt; 325 mg/day) or other non-steroidal anti-inflammatory drugs&#xD;
             (NSAID) known to inhibit platelet function (within 10 days prior to first dose of&#xD;
             study treatment)&#xD;
&#xD;
         11. Recent or current receive treatment of oral all doses of oral or parenteral&#xD;
             anticoagulants or thrombolytic agent. Prophylactic use of anticoagulants is permitted.&#xD;
&#xD;
         12. History or evidence of inherited bleeding diathesis or coagulopathy or thrombus&#xD;
&#xD;
         13. Uncontrolled hypertension (SBP&gt;140 mmHg and/or diastolic blood pressure&gt;90 mmHg),&#xD;
             prior history of hypertensive crisis and hypertensive encephalopathy&#xD;
&#xD;
         14. Clinically significant cardiovascular disease but not limited to active infections;&#xD;
             unstable angina; stroke or transient cerebral ischemia (within 6 months prior to&#xD;
             screening); myocardial infarction (within 6 months prior to screening) ; congestive&#xD;
             heart-failure (New York Heart Association (NYHA) class≥ II) ; serious cardiac&#xD;
             arrhythmia, hepatic, renal or metabolic disease requiring medication during the study.&#xD;
&#xD;
         15. History of peptic ulcer, gastrointestinal perforation, erosive esophagitis, erosive&#xD;
             gastritis, inflammatory bowel disease or diverticulitis, abdominal fistula or&#xD;
             intra-abdominal abscess within 6 months prior to screening&#xD;
&#xD;
         16. Patient diagnosed with a tracheo-esophageal fistula&#xD;
&#xD;
         17. Clinically significant third space effusion (e.g., uncontrolled ascites or pleural&#xD;
             effusion by extraction or other treatment)&#xD;
&#xD;
         18. Pulmonary fibrosis or active pneumonia showed by CT at baseline&#xD;
&#xD;
         19. Active malignancy other than non-small cell lung cancer (NSCLC), treated carcinoma in&#xD;
             situ of the cervix, superficial basal cell or squamous cell carcinoma, radical surgery&#xD;
             of localized prostate cancer, radical surgery of ductal carcinoma in situ within 5&#xD;
             years prior to randomization&#xD;
&#xD;
         20. Known autoimmune disease&#xD;
&#xD;
         21. Known positive HbsAg and hepatitis B virus (HBV)-DNA drop test in peripheral blood ≥ 1&#xD;
             x 10^3 copy number/L or 200 IU/mL; If HBsAg positive and HBV-DNA drop test in&#xD;
             peripheral blood &lt; 1 x 10^3 copy number/L or 200 IU/mL, patient is considered to be&#xD;
             eligible by investigator only when chronic hepatitis B in the plateau and do not&#xD;
             increase the risk&#xD;
&#xD;
         22. Known positive HIV or hepatitis C virus (HCV) or syphilis&#xD;
&#xD;
         23. Known allergic disease or allergic physique&#xD;
&#xD;
         24. Treatment with any other investigational agent or participation in another clinical&#xD;
             trial within 30 days prior to screening&#xD;
&#xD;
         25. Known alcoholism or drug abuse&#xD;
&#xD;
         26. Pregnant or anticipation of pregnant during the study or lactating women&#xD;
&#xD;
         27. Known hypersensitivity to bevacizumab or any of its excipients and/or any of the&#xD;
             chemotherapy agents&#xD;
&#xD;
         28. Other conditions that the investigator thinks unsuitable in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center; Sun Yat sen University;</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <results_first_submitted>July 6, 2020</results_first_submitted>
  <results_first_submitted_qc>November 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 8, 2020</results_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02954172/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02954172/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab in Combination With Paclitaxel/Carboplatin</title>
          <description>Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>IBI305 in Combination With Paclitaxel/Carboplatin</title>
          <description>Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>allergic reaction</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-measurable lesions at baseline</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab in Combination With Paclitaxel/Carboplatin</title>
          <description>Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>IBI305 in Combination With Paclitaxel/Carboplatin</title>
          <description>Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="220"/>
            <count group_id="B2" value="221"/>
            <count group_id="B3" value="441"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Mean (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="8.69"/>
                    <measurement group_id="B2" value="57.2" spread="9.28"/>
                    <measurement group_id="B3" value="57.4" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Han</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.93" spread="8.166"/>
                    <measurement group_id="B2" value="164.03" spread="7.829"/>
                    <measurement group_id="B3" value="164.48" spread="8.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.16" spread="10.844"/>
                    <measurement group_id="B2" value="62.14" spread="10.272"/>
                    <measurement group_id="B3" value="62.15" spread="10.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate</title>
        <description>ORR（objective response rate）was defined as the percentage of participants in the analysis population who had a Complete Response or a Partial Response per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Overall Response (OR) = CR + PR.</description>
        <time_frame>18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab in Combination With Paclitaxel/Carboplatin</title>
            <description>Drug Bevacizumab 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>IBI305 in Combination With Paclitaxel/Carboplatin</title>
            <description>Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>ORR（objective response rate）was defined as the percentage of participants in the analysis population who had a Complete Response or a Partial Response per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Overall Response (OR) = CR + PR.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4"/>
                    <measurement group_id="O2" value="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>the equivalence margin of the ORR ratio was set at (0.75, 1.33).</non_inferiority_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.756</ci_lower_limit>
            <ci_upper_limit>1.077</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Time</title>
        <description>OS was defined as the time from randomization to death due to any cause.</description>
        <time_frame>18.020 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab in Combination With Paclitaxel/Carboplatin</title>
            <description>Drug Bevacizumab 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>IBI305 in Combination With Paclitaxel/Carboplatin</title>
            <description>Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Time</title>
          <description>OS was defined as the time from randomization to death due to any cause.</description>
          <units>month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="18.020" lower_limit="16.73" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <p_value>0.7066</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by Independent Radiological Review Committee.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab in Combination With Paclitaxel/Carboplatin</title>
            <description>Drug Bevacizumab 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>IBI305 in Combination With Paclitaxel/Carboplatin</title>
            <description>Drug IBI30515mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by Independent Radiological Review Committee.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.260" lower_limit="6.810" upper_limit="8.500"/>
                    <measurement group_id="O2" value="8.430" lower_limit="7.170" upper_limit="9.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <p_value>0.3497</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through study completion, an average of 2 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab in Combination With Paclitaxel/Carboplatin</title>
          <description>Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
        </group>
        <group group_id="E2">
          <title>IBI305 in Combination With Paclitaxel/Carboplatin</title>
          <description>Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart-failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Ventricular premature contraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Wolfe-parkinson-white syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hydropericardium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle-closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Meibomianitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Retinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Esophageal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Saprodontia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis occurs almost instantaneously</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>pulmonary infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Infectious Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Device associated infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>The anus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Phthisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tracheorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Fever infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Decreased platelet count</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Lower white blood cell count</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Neutrophils count decreased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase is elevated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase was elevated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyl transferase is elevated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Haemoglobin reduction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood bilirubin is elevated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoproteinemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Reduced food intake</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Gout joint inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Central nervous system metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>lymphangitis carcinomatosa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Neurophlegmon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Debilitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bronchorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Breathing difficulties</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Expectoration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Distal embolization</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Limb vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="216" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Lymphocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoesthesia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleeplessness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yi Bo</name_or_title>
      <organization>Innovent Biologics (Suzhou) Co., Ltd. (seal)</organization>
      <phone>+86 13382419112</phone>
      <email>jessica.yi@innoventbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

